A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib-Reference-Cited by-同舟云学术

A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib

Published:2022-06 Issue:4 Volume:23 Page:300-310
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Camidge D. Ross,Moran Teresa^ORCID,Demedts Ingel,Grosch Heidrun,Mileham Kathryn^ORCID,Molina Julian,Juan-Vidal Oscar^ORCID,Bepler Gerold,Goldman Jonathan W^ORCID,Park Keunchil^ORCID,Wallin Johan,Wijayawardana Sameera R^ORCID,Wang Xuejing Aimee,Wacheck Volker,Smit Egbert

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference41 articles.

1. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers;Shigematsu H;Int J Cancer,2006

2. Gefitinib Or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced egfr mutation-positive non-small-cell lung cancer (eurtac): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

4. Phase iii study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with egfr mutations;Sequist;J Clin Oncol,2013

5. Osimertinib in untreated egfr-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of an Engineered Single-Domain Antibody for Targeting MET in Non-Small Cell Lung Cancer;Bioconjugate Chemistry;2024-03-12

2. Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study;BMC Pulmonary Medicine;2024-02-24

3. Effect of Erlotinib Combined with Radiotherapy on Proliferation and Apoptosis of Human Non-Small Cell Lung Cancer Cells and its Possible Mechanism Exploration;Indian Journal of Pharmaceutical Sciences;2024

4. Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review;Translational Cancer Research;2023-12

5. A Meta-analysis of Randomised Controlled Trials Comparing Combination Therapy as Second-line Treatment With Monotherapy in Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation;American Journal of Clinical Oncology;2023-10-02